Moderate coding expectations
Solutions Architects face lighter coding rounds than SWEs, focusing on architectural thinking and design patterns rather than complex algorithms.
0 roles from funded startups and hidden sources. Posted
minutes ago. Updated every 60 seconds
Focus areas that matter most for Solutions Architect positions at enterprise and cloud companies.. Explore key insights and preparation tips to help you excel in your interview process.
Solutions Architects face lighter coding rounds than SWEs, focusing on architectural thinking and design patterns rather than complex algorithms.
Deep dives into enterprise patterns, cloud architectures, and scalability trade-offs. This is the core competency tested.
Cloud Patterns
Multi-cloud and hybrid architectures
Enterprise Integration
APIs, messaging, and data flow
Scalability Design
Load balancing and distributed systems
Different companies emphasize different architectural domains based on their technology stack and business needs.
AWS, Microsoft, Google
Cloud-native patterns and service architectures
Salesforce, Oracle, SAP
Enterprise integration and platform design
Compare cost-of-living buying power and how crowded the market is versus other major tech cities—so you can focus your search where the odds fit your goals.
Baltimore offers approximately 70% lower housing costs compared to San Francisco, with median home prices around $200K versus $1.4M in the Bay Area. Solutions Architects can achieve superior ROI on their $145K+ salaries while enjoying waterfront living and a 30-minute commute to Washington DC's tech corridor.
Baltimore's Solutions Architect market remains undersaturated compared to traditional tech hubs, creating excellent opportunities for experienced professionals to stand out.

New roles go live every minute and the earliest applicants win. Get the freshest, verified listings delivered straight to your inbox before most job seekers ever see them.
👉 Get free daily job postsPearl Diagnostics is a Baltimore-based biotech spun out of Johns Hopkins University in 2014 that builds non-invasive urine-based diagnostic tests for lung infections. Its flagship MycoMEIA Aspergillus urine assay, which received FDA 510(k) clearance in August 2025 and CE approval for the EU, replaces invasive bronchoalveolar lavage procedures used to detect aspergillosis in transplant recipients, cancer patients, and immunocompromised individuals. The company is extending the same antigen-detection platform to other fungal and bacterial pathogens, including a Pseudomonas assay for cystic fibrosis patients.
Raised
$11.2M
Series A · 2026
Key contacts
-
Leadership & hiring contacts indexed
HQ market
Baltimore, Maryland
United States